AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19005687
Drug: 2.0 g
RxNorm normalized name: Fifty50 2.0 Glucose Meter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 g ginger daily
Trial: 16849757
Drug: Oral fenretinide
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fenretinide at 2,475 mg/m2 per day for 7 days, repeated every 21 days.
Trial: 16849757
Drug: Oral fenretinide
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fenretinide at 3,300 mg/m2 per day (highest dose tested).
Trial: 16849757
Drug: Oral fenretinide
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fenretinide at 1,050 mg/m2.
Trial: 16849757
Drug: Oral fenretinide
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fenretinide at 1,860 mg/m2.
Trial: 16849757
Drug: Oral fenretinide
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fenretinide at 2,475 mg/m2.
Trial: 9221964
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg; 2g/kg and then 1 g/kg every three weeks)
Trial: 9221964
Drug: Recombinant interferon‐alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon‐alpha (IFN‐alpha; 3 MU/m2 subcutaneously three times weekly)
Trial: 2886534
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose iv mezlocillin (5.0 g)
Trial: 2886534
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of iv cefuroxime plus metronidazole
Trial: 28616797
Drug: Bimatoprost/timolol maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimatoprost/timolol maleate fixed combination (BTFC)
Trial: 28616797
Drug: Latanoprost/timolol maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost/timolol maleate fixed combination (LTFC)
Trial: 19019932
Drug: Travoprost/timolol maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Travoprost/timolol maleate fixed combination (TTFC)
Trial: 25008885
Drug: Sildenafil [1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil [1 mg/(kg . d)] three times daily for 7‐10 days
Trial: 20569928
Drug: Copper glycinate
RxNorm normalized name: copper glycinate
DrugBank: Cupric glycinate (DB11509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper glycinate (2 mg copper/day) for 8 weeks
Trial: 16351509
Drug: High-isoflavone soy
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-isoflavone soy diet (113-207 mg/day total isoflavones)
Trial: 16351509
Drug: Low-isoflavone soy
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-isoflavone soy diet (<5 mg/day total isoflavones)
Trial: 12351534
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg Org 31710
Trial: 10078088
Drug: captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: captopril 25 mg three times daily
Trial: 1971872
Drug: Gastric delivery
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric delivery system (GDS) for iron supplementation, 50 mg daily
Trial: 1971872
Drug: Conventional ferrous
RxNorm normalized name: Ferrous Fumarate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional ferrous sulphate, 50 mg daily
Trial: 722473
Drug: Phenobarbital (tranquilizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (tranquilizer condition)
Trial: 31589645
Drug: Potassium iodide
RxNorm normalized name: Potassium Iodide
DrugBank: Potassium Iodide (DB06715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Potassium iodide capsule (225 μg iodine) daily for 26 weeks
Trial: 31589645
Drug: Iodized salt
RxNorm normalized name: calcium iodized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodized salt weekly for 26 weeks
Trial: 28925046
Drug: Aqueous extract
RxNorm normalized name: green tea aqueous extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous extract of Hibiscus sabdariffa (AEHS) 250 mg/kg and simvastatin 10 mg/kg
Trial: 28925046
Drug: Aqueous extract
RxNorm normalized name: green tea aqueous extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous extract of Hibiscus sabdariffa (AEHS) 500 mg/kg and simvastatin 20 mg/kg
Trial: 28925046
Drug: Aqueous beverage
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous beverage of Hibiscus sabdariffa (ABHS) with single-dose simvastatin 40 mg
Trial: 26281572
Drug: Fangfeng Tongsheng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fangfeng Tongsheng granule (3 g, twice a day for 14 days)
Trial: 26281572
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control (simulated agent granules, 3 g, twice a day for 14 days)
Trial: 21681103
Drug: 17.5 mg
RxNorm normalized name: acitretin 17.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17.5 mg transdermal nicotine (TDN) patch
Trial: 21681103
Drug: Placebo (drug‐free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (drug‐free bandage)
Trial: 17403842
Drug: Dexamethasone (0.89
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.89 mg/kg over 10 days)
Trial: 11507005
Drug: Arginine vasopressin
RxNorm normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine vasopressin (AVP) following V(1) receptor blockade
Trial: 10987239
Drug: Liposuction (LS)
RxNorm normalized name: bisoprolol fumarate Oral Tablet [Emcor LS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposuction (LS) combined with Controlled Compression Therapy (CCT)
Trial: 6325044
Drug: Ketanserin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (10 mg iv)
Trial: 29579331
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg daily
Trial: 22157367
Drug: Vinorelbine 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 60 mg/m on days 1 and 8 every 3 weeks
Trial: 19944151
Drug: 1 x
RxNorm normalized name: Black Cohosh 1 X Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 10(8)TCID(50) IMVAMUNE dose
Trial: 19944151
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three IMVAMUNE doses
Trial: 26927900
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron sulfate
Trial: 2152594
Drug: Intranasal calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal calcitonin 200 IU plus calcium 500 mg daily for 2 years
Trial: 2152594
Drug: Intranasal calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal calcitonin for 1 year
Trial: 2152594
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (19 age-matched women, no treatment)
Trial: 2152594
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of calcitonin treatment for 1 year
Trial: 27191693
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training (15-20 minutes of aerobic exercise plus 40 minutes of resistance exercise), 3 times per week, for 16 weeks.
Trial: 21933039
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training
Trial: 24354547
Drug: Brief intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief intervention as part of a National Institute on Drug Abuse‐funded clinical trial of a screening and brief intervention protocol
Trial: 21096475
Drug: Robotic rehabilitation
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic rehabilitation that delivers movement therapy
Trial: 12052800
Drug: Daily elemental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily elemental zinc (10 mg for infants, 20 mg for older children)
Trial: 9180409
Drug: Hydrosystem (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrosystem (topical surfactant)
Trial: 6350475
Drug: Intravenous acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acyclovir (ACV)
Trial: 28732435
Drug: Oral levamisole
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral levamisole (50 mg twice a day for two weeks with each vaccination)
Trial: 24821457
Drug: Lipoic acid
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipoic acid (1,200 mg/day)
Trial: 22292370
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine nursing treatment)
Trial: 8034816
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (5 group sessions over 8 weeks)
Trial: 20051714
Drug: Substance P
RxNorm normalized name: Substance P
DrugBank: Substance P (DB19198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance P (10(‐5) mol/l)
Trial: 20051714
Drug: Substance P
RxNorm normalized name: Substance P
DrugBank: Substance P (DB19198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance P (10(‐6) mol/l)
Trial: 16109077
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg oral ascorbic acid 3x/week for 8 weeks (n=10)
Trial: 16109077
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg intravenous ascorbic acid 3x/week for 8 weeks (n=11)
Trial: 16109077
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg oral ascorbic acid 3x/week for 3 months (n=70)
Trial: 16109077
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (n=83)
Trial: 10425594
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg of ondansetron
Trial: 10425594
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg of dimenhydrinate
Trial: 7814759
Drug: Mandibular implant-retained
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mandibular implant-retained overdentures
Trial: 11837089
Drug: Mandibular overdenture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular overdenture retained by two IMZ-implants (implant-mucosa-borne)
Trial: 11837089
Drug: Mandibular overdenture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular overdenture on a transmandibular implant (TMI; mainly implant-borne)
Trial: 6452987
Drug: Meclocycline sulfosalicylate
RxNorm normalized name: Meclocycline Sulfosalicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meclocycline sulfosalicylate cream, 1 percent, applied twice daily
Trial: 6452987
Drug: Meclocycline sulfosalicylate
RxNorm normalized name: Meclocycline Sulfosalicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meclocycline sulfosalicylate cream, 1 percent
Trial: 31021451
Drug: Model-free digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model-free digital workflow using digital impressions immediately after implant placement
Trial: 21118309
Drug: Methotrexate (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (initial dose, 15 mg per week)
Trial: 21118309
Drug: Cyclosporine (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (initial dose, 5 mg per kg of bodyweight per day)
Trial: 12082657
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 4,000 to 10,000 IU by subcutaneous injection 3 times weekly
Trial: 12082657
Drug: Oral indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral indomethacin 50 mg twice daily (Control group)
Trial: 10532092
Drug: Letrozole 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 0.5 mg once daily
Trial: 9681078
Drug: Aminoglutethimide 250
RxNorm normalized name: aminoglutethimide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide 250 mg twice daily
Trial: 8006395
Drug: Prednisone (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (0.6 to 0.3 mg/kg per day for 1 month) followed by interferon alfa‐2a (3 MU/m2, thrice weekly, for 12 months)
Trial: 2456731
Drug: Chlorproguanil with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorproguanil with folate supplements
Trial: 2456731
Drug: Maloprim with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maloprim with folate supplements
Trial: 2456731
Drug: Chlorproguanil without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorproguanil without folate supplements
Trial: 29668608
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 μg/kg (group D1)
Trial: 29668608
Drug: Dexmedetomidine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1.5 μg/kg (group D2)
Trial: 29668608
Drug: Dexmedetomidine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 2 μg/kg (group D3)
Trial: 21307769
Drug: Intrathecal hyperbaric
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal hyperbaric bupivacaine (5, 6, 7, 8, 9, 10, or 11 mg) coadministered with 200 μg morphine and 10 μg fentanyl
Trial: 21307769
Drug: Intrathecal hyperbaric
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal hyperbaric bupivacaine (low doses)
Trial: 19190211
Drug: Primaquine 0.58
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine 0.58 mg/kg/d
Trial: 19190211
Drug: Primaquine 0.83
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine 0.83 mg/kg/d
Trial: 19190211
Drug: Primaquine 1.17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine 1.17 mg/kg/d
Trial: 16794504
Drug: 6 courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 courses of chemotherapy (nitrogen mustard, oncovin, prednisone, procarbazine/doxorubicin, bleomycin, vinblastine, dacarbazine)
Trial: 16794504
Drug: 4 courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 courses of chemotherapy (nitrogen mustard, oncovin, prednisone, procarbazine/doxorubicin, bleomycin, vinblastine, dacarbazine) + 2550 cGy involved‐field radiotherapy
Trial: 16794504
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and chemoradiotherapy
Trial: 11938825
Drug: Shenlong Oral
RxNorm normalized name: CAMPHOR (SYNTHETIC) 4.28 mg in 100 mg / MENTHOL 2.84 mg in 100 mg / METHYL SALICYLATE 1.4 mg in 100 mg TRANSDERMAL PLASTER [Shennong Analgesic Plaster]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenlong Oral Liquid (SLOL) combined with radiotherapy
Trial: 9506009
Drug: Investigational transdermal
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational transdermal testosterone systems
Trial: 3618133
Drug: Doxycycline treatment
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline treatment preoperatively
Trial: 19212170
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no preoperative treatment)
Trial: 26280823
Drug: Extra Virgin
RxNorm normalized name: Jarrow Formulas Extra Virgin Coconut Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra Virgin Olive Oil (EVOO) 50 mL daily for 20 days
Trial: 26280823
Drug: Refined Olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refined Olive Oil (ROO) 50 mL daily for 20 days
Trial: 23766338
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) monotherapy 400/100 mg twice daily
Trial: 18672538
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) monotherapy
Trial: 23766338
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (zidovudine/lamivudine 300/150 mg twice daily)
Trial: 15877670
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (125 mg of ferric gluconate per treatment)
Trial: 15877670
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no iron administration)
Trial: 15877670
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron and Control
Trial: 16606452
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg repaglinide
Trial: 31709648
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg glipizide
Trial: 11678967
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg glibenclamide
Trial: 12587769
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three drugs
Trial: 3393916
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with cisplatin, bleomycin, and methotrexate/leucovorin (PBM) before local regional treatment
Trial: 3393916
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with cisplatin and infusion 5-fluorouracil
Trial: 3393916
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with PBM after surgery and/or radiotherapy
Trial: 17325557
Drug: Early parenteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early parenteral nutrition (1.0 g/kg/d amino acids starting within the first day and 1.0 g/kg/d lipid added the next day)
Trial: 17325557
Drug: Conventional nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional nutrition (10% glucose and electrolytes in the first 72 hours, followed by 0.5 g/kg/d amino acids and lipid)
Trial: 14741063
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg intravenously over 30 min)
Trial: 11480793
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 600 mg/day
Trial: 7826055
Drug: 200-ml milkshake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-ml milkshake preload
Trial: 3046889
Drug: Brand A
RxNorm normalized name: Select Brand Aspirin 325mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brand A levothyroxine sodium tablets
Trial: 3046889
Drug: Brand B
RxNorm normalized name: Select Brand Bulk-Forming Laxative Powder for Suspension (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brand B levothyroxine sodium tablets
Trial: 29663458
Drug: Vaccine schedule
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine schedule A (0, 1, and 2 months)
Trial: 29663458
Drug: Vaccine schedule
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine schedule B (0, 1, and 6 months)
Trial: 29663458
Drug: Vaccine schedule
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine schedule C (0, 1, and 12 months)
Trial: 23730838
Drug: 420 mg
RxNorm normalized name: choline 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 420 mg silymarin three times a day
Trial: 23730838
Drug: 700 mg
RxNorm normalized name: cystine 700 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700 mg silymarin three times a day
Trial: 15888560
Drug: Subcutaneous ghrelin
RxNorm normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous ghrelin (3.6 nmol/kg)
Trial: 10613617
Drug: 2 microg
RxNorm normalized name: Beta 2 microglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 microg 1,25-dihydroxyvitamin D3 administered at 8 AM
Trial: 10613617
Drug: 2 microg
RxNorm normalized name: Beta 2 microglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 microg 1,25-dihydroxyvitamin D3 administered at 8 PM
Trial: 10613617
Drug: Control (pre-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (pre-dose measurements)
Trial: 7604800
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg once daily
Trial: 11018193
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg once daily